Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 83, Issue 3, 2012, Pages 282-287

  Goodin, Douglas S ^a   Traboulsee, Anthony ^b   Knappertz, Volker ^c,d,e   Reder, Anthony T ^f   Li, David ^b   Langdon, Dawn ^g   Wolf, Christian ^h   Beckmann, Karola ^c   Konieczny, Andreas ⁱ   Ebers, George C ^j  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BAYER CORPORATION   (United States)

^d BAYER PHARMA AG   (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f UNIVERSITY OF CHICAGO   (United States)

^g UNIVERSITY OF LONDON   (United Kingdom)

^h Lycalis Bruxelles   (Belgium)

ⁱ Lampe Konieczny and Company   (Germany)

^j JOHN RADCLIFFE HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON BETA SERINE;

ADULT; ARTICLE; BRAIN ATROPHY; COGNITION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHYSICAL DISABILITY; PRIORITY JOURNAL; RELAPSE;

ADULT; COGNITION; DISABLED PERSONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TESTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84862776780     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2011-301178     Document Type: Article

References (28)

1. Baker SG, Kramer BS. A perfect correlate does not a surrogate make. BMC Med Res Methodol 2003;3:16.
2. Fleming TR, DeMets DL. Surrogate endpoints in clinical trials: Are we being misled? Ann Intern Med 1996;125:605-13. (Pubitemid 126450094)
3. Bucher HC, Guyatt GH, Cook DJ, et al. Users guide to the medical literature XIX: applying clinical trial results: a. how to use an article measuring the effect of an intervention on surrogate endpoints. JAMA 1999;282:771-8. (Pubitemid 29404385)
4. Fleming TR. Surrogate endpoints in cardiovascular disease trials. Am Heart J 2000;139:S193-6. (Pubitemid 30207818)
5. Sormani MP, Bonzano L, Roccatagliata L, et al. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytical approach. Ann Neurol 2009;65:268-75.
6. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61.
7. Paty DW, Li DK. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and IFNB Multiple Sclerosis Study Group. Neurology 1993;43:662-7.
8. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-85.
9. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-52. (Pubitemid 14237132)
10. Graves RM. Survey errors and survey costs. New York: John Wiley and Sons, 1989.
11. Goodin DS, Jones J, Li D, et al; for the investigators of the 16-Year Long-Term Follow-Up Study. Establishing long-term efficacy in chronic disease: the use of recursive partitioning and propensity score adjustment to estimate long-term outcome in multiple sclerosis. PLoS One 2011;6:e22444.
12. Ebers G, Reder A, Traboulsee A, et al; for the investigators of the 16-Year Long-Term Follow-Up Study. Long-term follow-up of the original interferon-b1b trial in multiple sclerosis: Design and lessons from a 16-year observational study. Clin Ther 2009;31:1724-36.
13. Ebers GC, Traboulsee A, Li D, et al; for the investigators of the 16-Year Long-Term Follow-Up Study. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry 2010;81:907-12.
14. Wechsler D. Wechsler Test of Adult Reading™(WTARTM) Scoring and Administration Manual. San Antonio, Texas: Psychological Corporation, 2001.
15. Lublin FD, Reingold SC. Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. National Multiple Sclerosis Society (USA) Task Force on placebo-controlled clinical trials in MS. Ann Neurol 2001;49:677-81.
16. Polman CH, Reingold SC, Barkof F, et al. Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology 2008;70:1134-40. (Pubitemid 351464771)
17. Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 1999;12:295-302. (Pubitemid 29378163)
18. Goodin DS. MRI as a surrogate outcome measure of disability in multiple sclerosis: Have we been overly harsh in our assessment? Ann Neurol 2006;59:597-605.
19. Summers M, Swanton J, Fernando K, et al. Cognitive impairment in multiple sclerosis can be predicted by imaging early in the disease. J Neurol Neurosurg Psychiatry 2008;79:955-8.
20. Furby J, Hayton T, Anderson V, et al. Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis. Mult Scler 2008;14:1068-75.
21. Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006;67:944-53. (Pubitemid 44454583)
22. Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002;59:1412-20. (Pubitemid 35285996)
23. Fisher E, Rudick RA, Cutter G, et al. Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Mult Scler 2000;6:373-7. (Pubitemid 32106796)
24. Fischer JS, Rudick RA, Cutter GR, et al. The multiple sclerosis functional composite measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999;5:244-50. (Pubitemid 29405620)
25. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple sclerosis severity score: using disability and disease duration to rate disease severity. Neurology 2005;64:1144-51.
26. Ebers GC, Heigenhauer L, Daumer M, et al. Disability as an outcome in MS clinical trials. Neurology 2008;71:624-31.
27. Young PJ, Lederer C, Eder K, et al Sylvia Lawry Centre for Multiple Sclerosis Research. Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis. Neurology 2006;67:804-8. (Pubitemid 44394193)
28. Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. Brain 2010;133:1914-29.